TRELEGY ELLIPTA

This brand name is authorized in Austria, Australia, Brazil, Canada, Estonia, Spain, Finland, France, Hong Kong, Croatia, Ireland, Israel, Italy, Japan, Lithuania, Netherlands, New Zealand, Poland, Romania, Singapore, Turkey, United Kingdom, United States

Active ingredients

The drug TRELEGY ELLIPTA contains a combination of these active pharmaceutical ingredients (APIs):

1
UNII JS86977WNV - FLUTICASONE FUROATE
 

Fluticasone furoate is a synthetic trifluorinated corticosteroid that possesses a very high affinity for the glucocorticoid receptor and has a potent anti-inflammatory action.

 
Read more about Fluticasone furoate
2
UNII 7AN603V4JV - UMECLIDINIUM BROMIDE
 

Umeclidinium is a long acting muscarinic receptor antagonist (also referred to as an anticholinergic). It is a quinuclidine derivative that is a muscarinic receptor antagonist with activity across multiple muscarinic cholinergic receptor subtypes. Umeclidinium bromide exerts its bronchodilatory activity by competitively inhibiting the binding of acetylcholine with muscarinic cholinergic receptors on airway smooth muscle.

 
Read more about Umeclidinium
3
UNII 40AHO2C6DG - VILANTEROL TRIFENATATE
 

Vilanterol is a selective long-acting, beta2-adrenergic agonist (LABA). The pharmacologic effects of beta2-adrenoceptor agonist active substances, including vilanterol, are at least in part attributable to stimulation of intracellular adenylate cyclase, the enzyme that catalyzes the conversion of adenosine triphosphate (ATP) to cyclic-3',5'-adenosine monophosphate (cyclic AMP). Increased cyclic AMP levels cause relaxation of bronchial smooth muscle and inhibition of release of mediators of immediate hypersensitivity from cells, especially from mast cells.

 
Read more about Vilanterol

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group Classification
R03AL08 R Respiratory system → R03 Drugs for obstructive airway diseases → R03A Adrenergics, inhalants → R03AL Adrenergics in combination with anticholinergics
Discover more medicines within R03AL08

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country Identification scheme Identifier(s)
AU Pharmaceutical Benefits Scheme 11379X
BR Câmara de Regulação do Mercado de Medicamentos 510620020054407, 510620020054507
CA Health Products and Food Branch 02474522
EE Ravimiamet 1756425, 1756436, 1756447
ES Centro de información online de medicamentos de la AEMPS 117123602
FI Lääkealan turvallisuus- ja kehittämiskeskus 391529, 406412
FR Base de données publique des médicaments 63047629
GB Medicines & Healthcare Products Regulatory Agency 349523
HK Department of Health Drug Office 65911
IE Health Products Regulatory Authority 24739
IL מִשְׂרַד הַבְּרִיאוּת 8257, 8997, 8998
IT Agenzia del Farmaco 045790019, 045790021, 045790033
JP 医薬品医療機器総合機構 2290804G1022, 2290804G2029, 2290804G3025, 2290804G4021
LT Valstybinė vaistų kontrolės tarnyba 1084477, 1084478, 1084479
NL Z-Index G-Standaard, PRK 149470
NZ Medicines and Medical Devices Safety Authority 19806, 22512
PL Rejestru Produktów Leczniczych 100396029
RO Agenția Națională a Medicamentului și a Dispozitivelor Medicale W64067001, W64067002, W64067003
SG Health Sciences Authority 15806P
TR İlaç ve Tıbbi Cihaz Kurumu 8699522553501, 8699522553525, 8699522553532, 8699522557158, 8699522557165, 8699522557172
US FDA, National Drug Code 0173-0887, 0173-0893

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.